EXPERIENCE OF USE OF NEOADJUVANT DOSE-INTENSIVE CHEMOTHERAPY WITH DOXORUBICIN AND CISPLATIN IN COMBINED TREATMENT OF LOCALLY ADVANCED CERVICAL CANCER: PROSPECTIVE SINGLE-CENTER NON-RANDOMIZED CONTROLLED STUDY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: to evaluate the results of the use of dose-intensive neoadjuvant chemotherapy (NACT) with doxorubicin and cisplatin in patients with locally advanced cervical cancer stage IB2-IIB. Methods. In the patients participating in the study, the efficacy and toxi-city of 3 cycles of intravenous dose-intensive NACT according to the AP scheme (cisplatin 75 mg/m2, doxorubicin 35 mg/m2) and subsequent radical surgical intervention in 62 (89%) cases were evaluated. Results. The study involved 70 patients with locally advanced cervical cancer at the age of 27-68 years (mean age, 45 years). Against the background of the treatment, an objective response was received from 58 (83%) patients. Progression of the disease was detected in 6 (8.6%) cases; relapse of the disease was diagnosed in 2 (2.8%) patients. Neoadjuvant therapy allowed to perform radical surgical intervention in 61 (87.1%) patients. The tumor pathomorphological response of various degrees was obtained in 58 (82.8%) cases; complete clinical regression of the tumor was confirmed by a complete pathomorphological response in 5 (7.14%) of these cases. The dose-intensive regimen of chemotherapy did not lead to significant complications at the pharmacological and surgical stages of treatment. Conclusion. Analysis of the study results has showed that dose-intensive NACT is an effective method and can be considered as an alternative to standard treatment of locally advanced cervical cancer.

Full Text

Restricted Access

About the authors

O. A Smirnova

N.N. Petrov National Medical Research Center of Oncology

Email: ssmirnova.oa@gmail.com

N. E Bondarev

N.N. Petrov National Medical Research Center of Oncology

A. S Petrova

N.N. Petrov National Medical Research Center of Oncology

K. D Guseinov

N.N. Petrov National Medical Research Center of Oncology

N. A Mikaya

N.N. Petrov National Medical Research Center of Oncology

A. S Artemyeva

N.N. Petrov National Medical Research Center of Oncology

T. V Gorodnova

N.N. Petrov National Medical Research Center of Oncology

E. A Nekrasova

N.N. Petrov National Medical Research Center of Oncology

O. E Lavrynovych

N.N. Petrov National Medical Research Center of Oncology

V. O Bashlyk

N.N. Petrov National Medical Research Center of Oncology

A. O Nyuganen

N.N. Petrov National Medical Research Center of Oncology

A. V Abramova

N.N. Petrov National Medical Research Center of Oncology

A. A Sidoruk

N.N. Petrov National Medical Research Center of Oncology

E. A Ulrikh

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

T. Yu Semiglazova

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

A. F Urmancheeva

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

I. V Berlev

N.N. Petrov National Medical Research Center of Oncology; North-Western State Medical University n.a. I.I. Mechnikov

References

  1. Torre L.A., Bray F., Siegel R.L., et al. Global Cancer Statistics, 2012. CA Cancer J. Clin. 2015; 65:87-108.
  2. Peters W.A., Liu P.Y., Barrett R.J., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol. 2005;23(21):4626-33.
  3. Ульрих Е.А., Тамбиева З.А., Урманчеева А.Ф., Моисеенко В.М. Качество жизни больных раком шейки матки I, II стадий после радикальных методов лечения. Вопросы онкологии. 2007;53(5):717-21.
  4. Rydzewska L., Tierney J., Vale C.L., Symonds P.R. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database System. Rev. 2012;12:CD007406. doi: 10.1002/14651858.CD007406.pub3.
  5. Dueck A.C., Mendoza T., Mitchell S., et al. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PROCTCAE) JAMA. Oncol. 2015;1(8):1051-59. doi: 10.1001/jamaoncol.2015.2639.
  6. Benedetti-Panici P., Scambia G., Greggi S., et al. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstet. Gynecol. 1988(Pt. 1):344-48.
  7. Benedetti-Panici P., Greggi S., Colombo A., et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J. Clin. Oncol. 2002;20(1):179-88.
  8. Choi Y.S., Sin J.I., Kim J.H., et al. Survival benefits of neoadjuvant chemotherapy followed by radical surgery versus radiotherapy in locally advanced chemoresistant cervical cancer. J. Korean. Med. Sci. 2006;21:683-89.
  9. Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials. Eur. J. Cancer. 2003;39(17):2470-86.
  10. U.S. National Library of Medicine. ClinicalTrials.gov. [электронный ресурс] Режим доступа: https:// clinicaltrials.gov/ct2/home.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Bionika Media